Nivagen Inc. accused Sun Pharmaceuticals Industries Ltd. of attempting to sabotage approval of one of its patents and later infringing two protected drug compositions with its Sezaby neonatal seizure treatment.
India-based Sun and its units make and sell Sezaby injections that contain compositions of lyophilized phenobarbital sodium like those in Nivagen’s US Patent Nos. 11,878,076 and 11,406,598,according to the complaint filed Tuesday in the US District Court for the Eastern District of Texas.
Sun launched Sezaby in the US in January 2023 to treat neonatal seizures in term and preterm infants, according to a company press release. The parent ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.